Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDC and IL-2 in Resectable Pancreatic Cancer
NCT05810792Phase 2Not yet recruiting
- Sponsor
- Sahlgrenska University Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Cytokines & Interferons, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of histamine dihydrochloride and aldesleukin in pancreatic cancer (PC), sponsored by Sahlgrenska University Hospital. Primary endpoint: Treatment-Emergent Adverse Events at 18 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
histamine dihydrochloridealdesleukin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05810792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810792.